## FREDUN PHARMACEUTICALS LIMITED

compassionate healthcare



## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 31.12.2012

Rs. In Lacs

						RS. III Lacs	
. 1		Quarter Ended			Nine Months Ended		Year Ended
		Unaudited			Unaudited		Audited
	PARTICULARS	31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012
1 1	Income from Operations						i
	a) Net Sales /IncomeFrom Operation (Net of Excise Duty)	474.85	374.04	344.43	1244,12	844.88	1167.54
	b) Other Operating Income	10.52	3.2	9.02	17.56	19.56	78.85
	Total income from operatoins (net)	485_37	377.24	353.45	1261.68	864.44	1246.39
	Expenses						ĺ
	a) Cost of Material Consumed	140.75	268.5	227.76	536.43	461.61	647.89
	b) Purchases of stock -in-trade	38.05			38.05		
	c) Changes in inventories of finished goods, work-in-						
	progress and stock in trade	(8.30)	(76.10)	(45.16)	9.12	(75.52)	(107.18)
	d) Employess benefits expenses	57.30	41.44	42.39	141.56	114.28	163.03
	epreciation and amortisation expenses	11.93	12.77	10.33	35.78	30.23	35.44
	f) omer Expenses	225.41	101.63	93.92	425.52	263.19	445.65
	Total expenses	465.14	348.24	329.24	1186.46	793.79	1184.83
3	Profitt/ (Loss) from operations before other income, finance	20.23	29.00	24.21	75.22	70.65	61.56
	Other income	_	-	_	-	~	-
	Profit/(Loss) from ordinary activities before financial costs	20.23	29.00	24.21	75.22	70.65	61.56
	Less : Finance Cost	18.77	24.05	20.45	65.16	57.31	85.48
	Profit/(Loss) from ordinary activities after financial costs but	1.46	4.95	3.76	10.06	13.34	(23.92)
8	Exceptional items	_	-	-	_	-	-
9	Profit/(Loss) from ordinary activities before tax (7-8)	1.46	4.95	3.76	10.06	13.34	(23.92)
	Tax Expenses	0.00	0.00	0.97	0.80	3.10	0.00
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	1.46	4.95	2.79	9.26	10.24	(23.92)
12	Extraordinary item (net of tax expenses)	-	-	-	-		-
13	Net Profit/(Loss) for the period (11-12)	1.46	4.95	2.79	9.26	10.24	(23.92)
	Paid up Equity Share Capital (Face Value of Rs-10/- each)	237.45	237.45	237.45	237.45	237.45	237.45
	Reserves excluding Revaluation Reserves	-	-	_	-	-	3.11
16	Earning per Share (EPS) (before & after extra ordinary				1		1
	- Basic/ Diluted Earning Per Share (Rs.)	0.06	0.21	0.12	0.39	0.43	0.00
A	1) Public Shareholding			440000		440000	440200
	umber of shares	440300	440300		1		1 1
	Creentage of shareholding	18.72	18. <b>7</b> 2	18.72	18.72	18.72	18.72
	2) Promoters and promotor group shareholding			]		]	
	a) Pledged/Encumbured				_	_	_
	- Number of shares - Percentage of shares (as a % of total shareholding of		_	_	I -	1 -	[ [
	- Percentage of shares (as a % of total share capital of the	l <u>-</u>	1 -	<u> </u>	! -	_	_
	b) Non-encumbered		_				]
	- Number of shares	1912100	1912100	1912100	1912100	1912100	1912100
	- Percentage of shares (as a % of total shareholding of	100%		1	Į.		100%
	- Percentage of shares (as a % of total share capital of the	81.28%	1	1		81.28%	81.28%

## NOTES:-

- 1) The above results were taken on record by the Board of Directors at the meeting held on 15.02.2013.
- 2) Previous year's figures have been regrouped/rearranged wherever necessary.
- 3) There are no investor's complaints pending & no investor's complaints were received by the company.

PLACE: MUMBAI DATE: 15.02.2013 FOR FREDUN PHARMACEUTICALS LIMITED

JOINT MANAGING DIRECTOR

Office: 26, Manoj Industrial Premises, G. D. Ambekar Marg, Wadala, Mumbai - 400 031. INDIA. Phone: 91-22-40318111 Fax: 91-22-40318133 E-mail: info@fredunpharma.com Web: www.fredunpharma.com

Factory 14,15,16, Zorabain Industrial Complex, Veoor, Palghar (E). Dist -Thane - 401 404, INDIA. Phone: 02525-253194 Fax: 02525-253193